Quick Facts: Spaverin

• Therapeutic Domain: May assist with the management of gastrointestinal, biliary, and urinary tract discomfort.
• Primary Action: Used to address the symptoms of smooth muscle spasms (cramps) in internal organs.
• Applicable Conditions: Indicated for functional disorders of the gastrointestinal tract and may be employed for renal or biliary colic.

---

What Spaverin Treats: Main Uses and Benefits

Spaverin is a medication designed to provide relief from smooth muscle spasms, which often manifest as discomfort or cramping in various parts of the body. Its primary role involves addressing these contractions, particularly within the gastrointestinal, biliary, and urinary systems.

The medication is indicated for the symptomatic management of gastrointestinal complaints, such as abdominal pain and cramps, especially those associated with functional disorders of the digestive tract. It may be used to help reduce the intensity of episodes related to conditions like irritable bowel syndrome (IBS).

Additionally, Spaverin is employed in the supportive management of pain associated with specific conditions involving involuntary muscle contractions. This includes discomfort arising from kidney stones (renal colic) and gallstones (biliary colic), where it works to assist in the relaxation of the smooth muscle tissue.

Regulatory References

1. Swissmedic Public Summary SwissPAR overview

Eligibility and Contraindication Rules

Official regulatory documents define strict criteria for the population eligible to use Spaverin (Drotaverine). Use is generally established for adults and adolescents (over 12 years of age). For children between 6 and 12 years, use is permitted under dose restrictions, but the medication is not recommended for children younger than 6 years due to lack of sufficient data.

Absolute Contraindications

Spaverin must not be used by individuals who meet any of the following regulatory contraindications:

• Patients with hypersensitivity to the active ingredient (Drotaverine) or any excipients.
• Patients diagnosed with Severe Hepatic Failure (severe liver disease).
• Patients diagnosed with Severe Renal Failure (severe kidney disease).
• Patients with Severe Cardiac Insufficiency (low output syndrome) or specific cardiac conduction disorders (e.g., AV block, cardiogenic shock).
• Patients with Porphyria.

Conditional Use and Restrictions

Use is not recommended for women who are pregnant or breastfeeding as safety data is not fully established. Use requires caution in patients with non-severe hepatic or renal impairment and those with Arterial Hypotension (low blood pressure). The medication is also not recommended for patients with Parkinson’s Disease due to potential co-administration risks documented in labeling.

Spaverin Interactions with other medicines and products

This section details the officially documented interaction patterns for Spaverin (Drotaverine hydrochloride) as established in government regulatory documents. The medication's interaction profile is primarily defined by pharmacodynamic effects, involving either reinforcement or antagonism with other substances. No co-administered drugs are explicitly classified as contraindicated combinations based on interaction risk, nor are mandatory timing separation rules documented in the official labeling.

Interacting Substance/Class	Official Interaction Pattern
Levodopa	Reduces antiparkinsonian activity, which is documented to potentially increase patient rigidity and tremor.
Other Spasmolytics	Pharmacodynamic effects are intensified, indicating an additive action with co-administered spasmolytics.
Hypotension-Inducing Agents	Intensifies the risk of hypotension caused by agents such as Tricyclic Antidepressants, Quinidine, and Procainamide.
Morphine	Reduces the spasmogenic activity of Morphine.

The regulatory profile confirms additive pharmacodynamic effects when Spaverin is used concurrently with analgesics, antimuscarinics, or benzodiazepines. The diagnostic agent Patent Blue may lower the therapeutic efficacy of Drotaverine. Additionally, the official labeling includes notes regarding population-specific considerations, advising caution for use in individuals with renal, hepatic, or cardiac dysfunction and in elderly people. The absence of documented CYP or transporter-based interactions, alongside the absence of food or herbal interactions, further defines the structure of the regulatory profile.

Targeted Inhibition of PDE4

The drug inhibits the enzyme Phosphodiesterase type 4 (PDE4) and, to a lesser extent, PDE3, within smooth muscle cells. This targeted interaction prevents the normal breakdown of the critical second messenger cyclic adenosine monophosphate (cAMP), causing its concentration to rise.

---

Disruption of the Intracellular Contraction Cascade

The resulting accumulation of cAMP initiates a specific cascade that leads to the inactivation of Myosin Light Chain Kinase (MLCK). Since MLCK is required for initiating myosin phosphorylation, this enzymatic disruption modifies the signaling pathway required for muscle fiber shortening.

---

Physiological Consequence: Reduction in Muscle Tension

By interfering directly with the Ca^2+-dependent contractile machinery at the cellular level, the overall mechanism results in a generalized reduction in smooth muscle tension across the systems where PDE4 is expressed. This action represents a direct modulation of a key physiological process.

Official Administration Routes and Forms

Spaverin is administered using two officially approved routes, each defined by the available pharmaceutical preparations. The primary forms are the oral route, utilizing 40 mg or 80 mg tablets, and the parenteral route, which uses a 20 mg/mL solution designed for intravenous (IV) or intramuscular (IM) injection. The selection of the route is based on the required speed of onset and the setting of care.

---

Standard Dosing Patterns and Frequency

For adults, the typical oral dosing pattern involves a total daily dose ranging from 120 mg to 240 mg. This total is routinely administered in 2 to 3 separate, divided doses over the course of the day. Oral doses can be taken independently of meals. The parenteral route, generally used under professional supervision, involves single doses of 40 mg, which may be repeated up to three times daily, adhering to a maximum daily limit of 240 mg.

---

Procedural and Population-Specific Rules

Specific procedural instructions apply to the injection: the intravenous form must be administered slowly to comply with proper use guidelines. Dosing rules are also defined for pediatric use: children between 6 and 12 years have a regulated maximum daily dose of 80 mg, while those over 12 have a maximum of 160 mg. This medicine is typically used for symptomatic, short-term relief, with specific clinical protocols defining treatment duration in some contexts.

Research evidence / Overview of Studies for Spaverin

Evidence for use in Functional Gastrointestinal Disorders (IBS)

Research for Spaverin (Drotaverine hydrochloride) was studied for its evaluation in symptoms related to Irritable Bowel Syndrome (IBS). Studies primarily employed short-term Randomized Controlled Trials (RCTs) and observational settings evaluating patient-reported experiences in adult populations. Studies monitored outcomes related to physical discomfort, documenting measured changes in pain scores and function (stool frequency). The follow-up durations were limited, and evidence is considered moderate, reflecting that certainty remains low regarding sustained, long-term outcomes.

---

Evidence for use in Acute Colic Pain

Research focusing on acute pain, such as that caused by renal colic (kidney stones) or biliary colic (gallstones), relies on a larger body of evidence, mainly consisting of Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity in adult populations. Spaverin was evaluated for the rapid, short-term symptom changes in acute spasms, monitoring the change in pain level and the frequency of requiring additional pain medication. This research base is rated as high. However, the research is specialized in addressing the immediate, acute phase, and did not focus on longer-term clinical outcomes of the underlying cause.

---

What is Still Uncertain About the Evidence Base

A key limitation is that long-term effects are not fully established for most indications, as follow-up durations were limited in many of the core studies. Evidence quality varies across studies, particularly for conditions like IBS, where findings were mixed on secondary measures such as daily functioning. Furthermore, comparative evidence is lacking in some areas, limiting the available research on performance relative to other options.

Common questions about Spaverin (FAQ)

Q: What is the main reason a doctor would prescribe Spaverin?

Spaverin is indicated for easing painful smooth muscle spasms in several body systems. Official regulatory uses describe spasms related to the biliary tract (such as gallstones) and the urinary tract (such as kidney stones).

It is also indicated as supportive treatment for spasms in gastrointestinal disorders and gynecological conditions like dysmenorrhoea.

---

Q: Is Spaverin only used for one type of condition?

No, the drug is officially indicated for more than one type of condition related to muscle spasm. Regulatory indications cover spasms associated with disorders in the biliary tract, the urinary tract, the gastrointestinal system, and certain gynecological conditions.

---

Q: How quickly should I expect Spaverin to start working?

After taking an oral dose, the drug typically reaches its peak concentration in the bloodstream within one to three hours.

While clinical research in specific settings has suggested an onset of action around 30 minutes, this timeframe can vary for individuals.

---

Q: How long does the effect of one dose of Spaverin usually last?

The elimination half-life of the drug is reported to be between approximately 7 and 12 hours, which is the time it takes for half of the drug to be cleared from the body.

Clinical research in some settings has suggested a duration of therapeutic effect around 4 hours.

---

Q: Can Spaverin be bought over the counter in some countries?

The legal status of this medicine varies widely depending on the country where it is marketed. In many regions where the drug is authorized, the tablet form may be available as an Over-The-Counter (OTC) medicine.

However, the injectable form typically remains prescription-only (Rx).

---

Q: Is Spaverin considered a pain reliever?

Spaverin's official classification is an antispasmodic agent (spasmolytic). This means its primary function is to relax the smooth muscles that are tightening painfully.

It relieves discomfort by stopping the spasm itself, rather than working as a traditional analgesic (pain reliever) like ibuprofen or acetaminophen.

---

Q: Is feeling drowsy a common side effect of Spaverin?

According to the official product information, side effects affecting the nervous system, such as headache and dizziness (vertigo), are generally classified as rare.

Official safety materials instruct that individuals who experience these effects should avoid potentially hazardous tasks, such as driving or operating machinery.

---

Q: Why might a doctor prefer Spaverin over other treatments for spasms?

Official regulatory documents describe Spaverin as a selective inhibitor of the PDE4 enzyme. This highly focused mechanism works directly on smooth muscles to achieve relaxation.

This targeted action is one characteristic that may distinguish it from other antispasmodics.

---

Q: Can I take Spaverin with Tylenol (Acetaminophen)?

Regulatory information confirms that the concurrent use of Spaverin with analgesics is known to have additive effects. Analgesics is the drug class that includes acetaminophen.

This indicates the effects of the two medications may work together when taken at the same time.

---

Q: What is the difference between Spaverin and Ibuprofen?

Spaverin is classified as an antispasmodic that relaxes smooth muscles by selectively inhibiting the PDE4 enzyme. Ibuprofen, by contrast, is generally classified as a non-steroidal anti-inflammatory drug (NSAID).

These two classifications describe fundamentally different pharmacological mechanisms for pain and inflammation.

---

Q: Is Spaverin related to or the same as drugs like Dicyclomine or Hyoscine?

Regulatory information indicates that Spaverin is a benzylisoquinoline derivative and is structurally related to Papaverine. Unlike drugs such as Hyoscine, Spaverin is classified as a non-anticholinergic antispasmodic.

---

Q: Can taking Spaverin affect the results of lab tests?

Official labeling notes a specific interaction risk with the diagnostic agent known as Patent Blue, which may reduce Spaverin's effectiveness.

No interaction is typically listed for common routine blood or urine laboratory results.

---

Q: Why do official documents advise caution when driving after taking Spaverin?

Caution regarding driving or operating machinery is officially advised because dizziness (vertigo) is a potential side effect listed in the drug's safety profile.

Official safety materials instruct that individuals who experience these effects should avoid potentially hazardous tasks, such as driving or operating machinery.

---

Q: Is it true that Spaverin is not approved in all countries?

Yes, this is true. Drotaverine (the active ingredient) is not currently approved by major regulatory agencies such as the U.S. FDA, the European Medicines Agency (EMA), or Health Canada.

However, it is widely approved and used in many other countries worldwide.

---

Q: Is there a maximum time someone is typically prescribed Spaverin?

The medicine is generally approved for symptomatic, short-term relief of muscle spasms. Official regulatory documents typically do not specify a single maximum duration of treatment.

How to Store and Dispose of Spaverin

All storage and disposal procedures for Spaverin (drotaverine hydrochloride) must align with official regulatory documentation to ensure the medicine's stability and public safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at a temperature not above 30°C.
Protection	Must be protected from light and moisture.
Packaging	Keep in the original container or outer carton.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Spaverin must be disposed of in accordance with local regulations for medicinal products. It is mandatory not to throw away any medicines via wastewater or household waste. The proper procedure is to utilize an official drug take-back program or return the product to a pharmacy for authorized disposal.